



(43) International Publication Date
25 June 2015 (25.06.2015)

(10) International Publication Number
WO 2015/092382 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) *A61K 35/74* (2015.01)
A61K 39/395 (2006.01) *A61K 39/04* (2006.01)

(21) International Application Number:

PCT/GB2014/053717

(22) International Filing Date:

16 December 2014 (16.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1322725.1 20 December 2013 (20.12.2013) GB

(71) Applicant: **IMMODULON THERAPEUTICS LIMITED** [GB/GB]; 475 Salisbury House, London Wall, London, Greater London EC2M 5QQ (GB).

(72) Inventors: **AKLE, Charles**; 22 Devonshire Place - B2, London, Greater London W1G 6JA (GB). **GRANGE, John**; 22 Devonshire Place - B2, London, Greater London W1G 6JA (GB). **BILYARD, Kevin**; 22 Devonshire Place - B2, London, Greater London W1G 6JA (GB).

(74) Agents: **GILL JENNINGS & EVERY LLP** et al.; The Broadgate Tower, 20 Primrose Street, London, Greater London EC2A 2ES (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: A CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY

(57) Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell *Mycobacterium*, for example, *M. vaccae* or *M. obuense*.



WO 2015/092382 A1